<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01767896</url>
  </required_header>
  <id_info>
    <org_study_id>7374-CL-0103</org_study_id>
    <nct_id>NCT01767896</nct_id>
  </id_info>
  <brief_title>Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine</brief_title>
  <official_title>Phase III Study of ASP7374 －Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMN Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMN Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare immunogenicity and safety of ASP7374 (cell-culture
      derived influenza vaccine) with those of approved egg-derived trivalent inactivated vaccine
      (TIV) in elderly subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>seroconversion rate of hemoagglutination inhibition (HI) antibody titer</measure>
    <time_frame>Day 29</time_frame>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>geometric mean titer (GMT) of HI antibody titer</measure>
    <time_frame>Day 29</time_frame>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>seroprotection rate of HI antibody titer</measure>
    <time_frame>Day 29</time_frame>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT ratio of HI antibody titer</measure>
    <time_frame>Day 1 and Day 29</time_frame>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>seroconversion rate of neutralizing antibody titer</measure>
    <time_frame>Day 29</time_frame>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>seroprotection rate of neutralizing antibody titer</measure>
    <time_frame>Day 29</time_frame>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of neutralizing antibody</measure>
    <time_frame>Day 29</time_frame>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT ratio of neutralizing antibody</measure>
    <time_frame>Day 1 and Day 29</time_frame>
    <description>evaluated for A/H1N1, A/H3N2, and B</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1020</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>ASP7374 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cell-culture-derived vaccine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIV group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>approved egg-derived TIV group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ASP7374</intervention_name>
    <description>subcutaneous (sc)</description>
    <arm_group_label>ASP7374 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>approved egg-derived TIV</intervention_name>
    <description>subcutaneous (sc)</description>
    <arm_group_label>TIV group</arm_group_label>
    <other_name>Influenza HA vaccine &quot;SEIKEN&quot;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically stable, as judged on the basis of history and concurrent diseases

          -  Subject understands procedure of the protocol and is willing to comply with the
             protocol

        Exclusion Criteria:

          -  Scheduled to receive another vaccine during the study

          -  Received influenza HA vaccine within 180 days prior to screening

          -  Received or scheduled to receive a live vaccine within 28 days prior to vaccination
             with the study vaccine, and received or scheduled to receive an inactivated vaccine or
             a toxoid within 7 days prior to vaccination with the study vaccine

          -  Diagnosis of immune deficit in the past, has a family member (within the third degree
             of kinship) with a diagnosis of congenital immunodeficiency syndrome

          -  Received one of the following medications or treatment prior to vaccination with the
             study vaccine: Interferon formulation, drugs which affect the immune system,
             corticosteroids, G-CSF, M-CSF, human immunoglobulin products, blood products

          -  History of anaphylactic shock or an allergic reaction such as generalized eruption due
             to food or drug (including vaccines) allergies, fever ≥39.0°C within 2 days after the
             previous vaccination (influenza vaccine and others)

          -  History of seizures

          -  History of Guillain-Barre syndrome or acute disseminated encephalomyelitis (ADEM)

          -  Confirmed diagnosis of influenza within 84 days prior to screening test

          -  Body temperature of ≥37.5°C on Day 1 (before vaccination)

          -  Immunological tests reveal positive HBs antigen, HCV antibody, and HIV antigen and/or
             antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2013</study_first_submitted>
  <study_first_submitted_qc>January 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2013</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

